Skip to main content
. 2016 Aug 23;24(9):1634–1643. doi: 10.1038/mt.2016.141

Figure 4.

Figure 4

Minimal residual disease (MRD) reduction after 4G7SDIE treatment. MRD was assessed by multiparameter flow cytometry and detection of individual clonal immunoglobulin and TCR gene rearrangements or bcr/abl translocation fusion genes by real-time quantitative PCR. The origin of the y-axis indicates the individual MRD-detection limit. Best response for each eligible patient #P1-10 is shown. The nonresponding patients #P11-14 are spared.